Journal September 17, 2026 7 min read

NAD+ vs 5-Amino-1MQ: what the research actually compares

A comparison of published research on NAD+ and 5-Amino-1MQ, covering what each compound is, what studies measured, where evidence is stronger, and what remains unknown.

peptides-pro Editorial

The formal name for the compound commonly referred to as NAD+ is nicotinamide adenine dinucleotide, a dinucleotide coenzyme with the molecular formula C21H27N7O14P2 and a molecular weight of approximately 663.43 g/mol. It is also known by synonyms including β-nicotinamide adenine dinucleotide, diphosphopyridine nucleotide, and DPN; it is classified as a redox coenzyme and enzyme cofactor, and its research-grade form is supplied as a lyophilized powder or solution for laboratory use. The formal name for the compound commonly referred to as 5-Amino-1MQ is 5-amino-1-methylquinolinium, a small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor with the molecular formula C10H11N2+ and a molecular weight of approximately 159.21 g/mol (as the cation); it is also known as 5-amino-1-methylquinolinium iodide or chloride depending on the salt form, and it is classified as a quinolinium derivative and enzyme inhibitor. The research on both compounds centres on nicotinamide adenine dinucleotide (NAD+) metabolism and the enzymes that regulate it, including nicotinamide phosphoribosyltransferase (NAMPT), nicotinamide mononucleotide adenylyltransferase (NMNAT), and nicotinamide N-methyltransferase (NNMT).

Research Studies

NAD+ and whole-blood NAD+ levels in healthy adults

A clinical trial is assessing the absorption, safety, and efficacy of an oral NAD+ supplement in healthy adults, with the primary question being the change in NAD+ levels in whole blood from baseline to day 56 between the NAD+ supplement and placebo groups [2]. Participants are asked to complete questionnaires, provide blood samples, consume either the NAD+ supplement or a placebo for 55 days, and have their endothelial function evaluated [2]. This study design allows for a direct comparison of systemic NAD+ availability following oral supplementation versus placebo in a healthy adult population.

NAD+ and measurement validation for clinical studies

A separate study aims to determine nicotinamide adenine dinucleotide (NAD) levels in healthy adult subjects before and after supplementing with over-the-counter nicotinamide riboside (NR) using magnetic resonance spectroscopy (MRS) [1]. This work focuses on validating NAD+ measurement methodologies for human clinical studies, which is a prerequisite for interpreting changes in NAD+ levels across different tissues and supplementation protocols [1].

NAD+ precursors and retinal protection in primary open-angle glaucoma

The NADIR trial is investigating whether high-dose vitamin B3 (nicotinamide) can protect retinal nerve cells in adults with primary open-angle glaucoma (POAG) who are already receiving standard glaucoma eye drops or laser treatment [3]. The main question is whether adding nicotinamide to standard glaucoma therapy slows the rate of thinning of the inner retinal nerve cell layer, measured by a non-invasive eye scan, compared to standard therapy alone over 12 months [3]. Participants are randomly assigned to receive nicotinamide tablets by mouth, starting at a lower dose of 1.5 grams per day [3]. This study examines a NAD+ precursor in a specific disease population with a structural endpoint.

NAD+ precursors and walking performance in peripheral artery disease

The NICE-PAD II trial is testing the hypothesis that among people with peripheral artery disease (PAD) age 50 and older, participants randomized to nicotinamide riboside (NR) will have greater improvement or less decline in six-minute walk distance at six-month follow-up compared to those randomized to placebo [4]. The study will randomize 250 participants with PAD age 50 and older to one of two groups for six months: nicotinamide riboside versus placebo [4]. The primary outcome is change in six-minute walk distance at six-month follow-up, and secondary outcomes include Walking Impairment Questionnaire (WIQ) distance score, PROMIS Mobility score, and calf muscle perfusion measured by magnetic resonance arterial spin labeling [4]. This trial provides a functional endpoint in a clinical population with vascular insufficiency.

NAD+ augmentation and safety in Down syndrome

A study is determining the safety and tolerability of different increasing doses of MIB-626, a microcrystalline form of β-nicotinamide mononucleotide (NMN), given daily for 28 consecutive days to adults with Down syndrome (DS) [8]. The study will also explore how the drug moves through the body over time (pharmacokinetics or PK) and how the drug affects the body in different ways (pharmacodynamics or PD) [8]. Participants are monitored for adverse events, and measurements to detect safety events include laboratory tests of blood counts, chemistries, and coagulation profile, and electrocardiogram (ECG) [8]. The trial will enroll a total of 24 adults with DS [8]. This work focuses on a specific NAD+ precursor in a population with a genetic predisposition to early Alzheimer's disease pathology.

NAD+ precursors and post-COVID syndrome

An observational study is investigating CICR-NAM, a special nicotinamide tablet that releases the active substance selectively in the lower intestine, as a food for special medicinal purposes in patients with post-COVID syndrome (PCS) [6]. In an earlier nutritional study, patients with COVID-19 recovered their physical performance more quickly when taking nicotinamide (vitamin B3), and patients who responded to nicotinamide also developed post-COVID syndrome less frequently [6]. Patients with post-COVID syndrome and documented tryptophan deficiency may therefore take one tablet of CICR-NAM [6]. This study examines a delayed-release NAD+ precursor in a post-infectious population.

5-Amino-1MQ and cancer models

No published clinical studies of 5-amino-1-methylquinolinium were identified in the evidence block. The evidence block does not contain any studies of 5-amino-1-methylquinolinium in cancer models or any other models. Therefore, no claims about its effects in cancer or any other disease can be made from the available evidence.

5-Amino-1MQ and metabolic models

No published clinical studies of 5-amino-1-methylquinolinium were identified in the evidence block. The evidence block does not contain any studies of 5-amino-1-methylquinolinium in metabolic models or any other models. Therefore, no claims about its effects on metabolism can be made from the available evidence.

5-Amino-1MQ and NNMT inhibition

No published clinical studies of 5-amino-1-methylquinolinium were identified in the evidence block. The evidence block does not contain any studies of 5-amino-1-methylquinolinium as an NNMT inhibitor or any other mechanism. Therefore, no claims about its mechanism of action can be made from the available evidence.

Comparative summary of evidence

The table below summarizes the evidence available for each compound from the provided sources.

Compound	Population/Model	Outcome Measured	Study Type	Source
NAD+ (oral supplement)	Healthy adults	Change in whole-blood NAD+ levels from baseline to day 56; endothelial function	Clinical trial	[2]
NAD+ (measurement validation)	Healthy adults	NAD levels before and after NR supplementation using MRS	Clinical study	[1]
Nicotinamide (NAD+ precursor)	Adults with primary open-angle glaucoma	Rate of thinning of inner retinal nerve cell layer over 12 months	Clinical trial	[3]
Nicotinamide riboside (NAD+ precursor)	People with peripheral artery disease age 50+	Change in six-minute walk distance at six months; WIQ; PROMIS; calf muscle perfusion	Clinical trial	[4]
Nicotinamide mononucleotide (NMN, MIB-626)	Adults with Down syndrome	Safety, tolerability, pharmacokinetics, pharmacodynamics	Clinical trial	[8]
Nicotinamide (CICR-NAM)	Patients with post-COVID syndrome	Observational outcomes related to tryptophan metabolism, energy metabolism, gut microbiome	Observational study	[6]
5-Amino-1-methylquinolinium	No studies identified in evidence block	Not applicable	Not applicable	—

Where the evidence is stronger for one compound

The evidence block contains multiple clinical studies of NAD+ and its precursors (nicotinamide, nicotinamide riboside, and nicotinamide mononucleotide) in various populations, including healthy adults, adults with primary open-angle glaucoma, people with peripheral artery disease, adults with Down syndrome, and patients with post-COVID syndrome [1][2][3][4][6][8]. These studies include randomized controlled trials with defined primary outcomes such as changes in whole-blood NAD+ levels, retinal nerve cell layer thickness, and six-minute walk distance [2][3][4]. In contrast, the evidence block contains no clinical studies of 5-amino-1-methylquinolinium. Therefore, the published work available in this evidence block is stronger for NAD+ and its precursors than for 5-amino-1-methylquinolinium.

What is simply not known

For 5-amino-1-methylquinolinium, the evidence block provides no information on its pharmacokinetics, pharmacodynamics, safety, tolerability, or efficacy in any population. No studies were identified that measured any outcome for this compound. For NAD+ and its precursors, while several clinical trials are ongoing or have been designed, the evidence block does not report the results of these trials. Therefore, the effects of NAD+ supplementation on whole-blood NAD+ levels, retinal nerve cell layer thickness, six-minute walk distance, safety, or any other outcome in the studied populations are not known from the evidence block. Additionally, the evidence block does not contain studies comparing NAD+ and 5-amino-1-methylquinolinium directly, so no comparative efficacy or safety conclusions can be drawn.

If you are reading this for personal health reasons

The compounds discussed here are sold for laboratory research purposes only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.